Progress in Treating DMD

Credit: University of Pittsburgh Medical Center Cross sections of muscle cells from a mouse treated with an adeno-associated virus vector carrying a mini-dystrophin gene (green area). Blue stains indicate cell nuclei. Gene therapy for Duchenne muscular dystrophy (DMD) has been particularly challenging because of the enormity of the dystrophin gene. Fitting the 3 million base pair behemoth into a viral vector is not unlike Prince Charming trying to shove large feet into Cinderella's tiny glass sl

Written byRicki Lewis
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Credit: University of Pittsburgh Medical Center Cross sections of muscle cells from a mouse treated with an adeno-associated virus vector carrying a mini-dystrophin gene (green area). Blue stains indicate cell nuclei. Gene therapy for Duchenne muscular dystrophy (DMD) has been particularly challenging because of the enormity of the dystrophin gene. Fitting the 3 million base pair behemoth into a viral vector is not unlike Prince Charming trying to shove large feet into Cinderella's tiny glass slipper. Trimming the gene is one approach, but determining which parts to snip has taken time. Assistant professor of molecular genetics and biochemistry at the University of Pittsburgh Xiao Xiao, research associate Bing Wang, and senior research associate Juan Li whittled the gene down to three "mini genes" of less than 4,000 bases each--small enough to fit adeno- associated virus (AAV) and enter enough skeletal muscle cells to prevent degeneration in a mouse model of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies